Breast cancer subtypes
|
RFS
|
OS
|
DMFS
|
---|
n
|
HR
|
P-value
|
n
|
HR
|
P-value
|
n
|
HR
|
P-value
|
---|
Total
|
3557
|
1.72 (1.54–1.94)
|
< 0.001
|
1117
|
1.86 (1.46–2.37)
|
< 0.001
|
1610
|
1.88 (1.53–2.32)
|
< 0.001
|
ER status
|
ER+
|
2766
|
1.77 (1.55–2.03)
|
< 0.001
|
377
|
2.74 (1.74–4.33)
|
< 0.001
|
577
|
2.89 (1.95–4.29)
|
< 0.001
|
ER-
|
788
|
1.03 (0.82–1.28)
|
0.81
|
142
|
0.91 (0.52–1.6)
|
0.74
|
170
|
1.04 (0.62–1.73)
|
0.89
|
PR status
|
PR+
|
525
|
2.02 (1.38–2.94)
|
< 0.001
|
0
|
–
|
–
|
122
|
1.35 (0.41–4.46)
|
0.62
|
PR-
|
483
|
1.42 (1.04–1.93)
|
0.027
|
2
|
–
|
–
|
95
|
2.24 (1.04–4.85)
|
0.035
|
HER2 status
|
HER2+
|
168
|
0.78 (0.46–1.32)
|
0.36
|
28
|
0.59 (0.19–1.83)
|
0.36
|
66
|
1.54 (0.61–3.91)
|
0.36
|
HER2-
|
756
|
1.78 (1.36–2.34)
|
< 0.001
|
62
|
0.92 (0.32–2.62)
|
0.87
|
82
|
2.43 (0.63–9.39)
|
0.18
|
ER+/PR+/HER2+
|
76
|
1.53 (0.33–7.09)
|
0.58
|
36
|
3.54 (0.41–30.58)
|
0.22
|
45
|
1.83 (0.36–9.47)
|
0.46
|
ER+/PR−/HER2+
|
26
|
0.47 (0.09–2.35)
|
0.35
|
–
|
–
|
–
|
–
|
–
|
–
|
ER+/PR+/HER2-
|
339
|
2.41 (1.48–3.93)
|
< 0.001
|
39
|
2.04 (0.18–22.51)
|
0.55
|
79
|
1.66 (0.33–8.22)
|
0.53
|
ER+/PR−/HER2-
|
77
|
1.47 (0.65–3.33)
|
0.35
|
–
|
–
|
–
|
–
|
–
|
–
|
ER−/PR−/HER2-
|
255
|
1.45 (0.9–2.34)
|
0.13
|
–
|
–
|
–
|
43
|
3.33 (0.67–16.58)
|
0.12
|
LN status
|
LN+
|
945
|
1.63 (1.3–2.03)
|
< 0.001
|
197
|
1.38 (0.84–2.28)
|
0.2
|
337
|
1.74 (1.14–2.65)
|
0.009
|
LN-
|
1813
|
1.67 (1.4–1.99)
|
< 0.001
|
425
|
2.41 (1.56–3.74)
|
< 0.001
|
896
|
2.42 (1.79–3.27)
|
< 0.001
|
Grade
|
1
|
308
|
2.52 (1.4–4.54)
|
0.0014
|
135
|
2.45 (0.86–6.96)
|
0.083
|
172
|
2.35 (0.94–5.84)
|
0.059
|
2
|
724
|
1.9 (1.45–2.49)
|
< 0.001
|
287
|
2.92 (1.76–4.86)
|
< 0.001
|
495
|
1.93 (1.34–2.78)
|
< 0.001
|
3
|
723
|
1.17 (0.91–1.51)
|
0.23
|
347
|
0.9 (0.6–1.34)
|
0.6
|
391
|
1.12 (0.77–1.64)
|
0.54
|
TP53 status
|
Mutated
|
188
|
0.91 (0.57–1.47)
|
0.71
|
111
|
0.95 (0.45–2.04)
|
0.91
|
83
|
0.8 (0.33–1.93)
|
0.62
|
Wild type
|
273
|
1.49 (0.97–2.28)
|
0.064
|
187
|
2.16 (1.1–4.23)
|
0.022
|
109
|
3.44 (1.44–8.22)
|
0.0031
|
- RFS Relapse free survival, OS Overall survival, DMFS Distant metastasis-free survival, HR Hazard ratio, − Ddata not available, LN Lymph node